PDF(Sci-hub)
Abstract：
To determine whether long-term, slow-release exposure to corticosteroids with Retisert promotes better surgical outcomes after Ahmed valve implantation.
This comparative retrospective cohort study included 17 study eyes (10 patients) with uncontrolled uveitis requiring Retisert and Ahmed implantation, and 55 control eyes (51 patients) with other types of medically uncontrolled glaucoma that only received Ahmed.
Main outcome measures were intraocular pressure (IOP), glaucoma eye drops per day, best-corrected visual acuity, early complications, and late complications at 1, 3, 6, and 12 months. Linear mixed effects models were used to model IOP, glaucoma drops per day, and visual acuity at 1 year after surgery.
At 1 year, the study eyes had a mean IOP of 12.24, which was lower than that for control eyes at 15.17 (P=0.04). At 1 year, the average number of glaucoma eye drops used per day for study eyes was 1.4, which was lower than that for control eyes at 2.3 (P=0.03). At 1 year, there were no statistically significant differences in change in visual acuity, early complications, and late complications between study and control eyes.
Patients who received a Retisert implantation had lower IOP and used fewer glaucoma eye drops compared with control eyes at 1-year post-Ahmed valve surgery. This study suggests that long-term, slow-release corticosteroid medication from Retisert (fluocinolone acetonide) may improve the surgical outcome for patients with an Ahmed valve implantation and/or Retisert helps control uveitis in patients with uveitic glaucoma receiving Ahmed valves.
This comparative retrospective cohort study included 17 study eyes (10 patients) with uncontrolled uveitis requiring Retisert and Ahmed implantation, and 55 control eyes (51 patients) with other types of medically uncontrolled glaucoma that only received Ahmed.
Main outcome measures were intraocular pressure (IOP), glaucoma eye drops per day, best-corrected visual acuity, early complications, and late complications at 1, 3, 6, and 12 months. Linear mixed effects models were used to model IOP, glaucoma drops per day, and visual acuity at 1 year after surgery.
At 1 year, the study eyes had a mean IOP of 12.24, which was lower than that for control eyes at 15.17 (P=0.04). At 1 year, the average number of glaucoma eye drops used per day for study eyes was 1.4, which was lower than that for control eyes at 2.3 (P=0.03). At 1 year, there were no statistically significant differences in change in visual acuity, early complications, and late complications between study and control eyes.
Patients who received a Retisert implantation had lower IOP and used fewer glaucoma eye drops compared with control eyes at 1-year post-Ahmed valve surgery. This study suggests that long-term, slow-release corticosteroid medication from Retisert (fluocinolone acetonide) may improve the surgical outcome for patients with an Ahmed valve implantation and/or Retisert helps control uveitis in patients with uveitic glaucoma receiving Ahmed valves.
摘要：
为了确定是否长期，使用Retisert缓释糖皮质激素可促进Ahmed瓣膜植入后更好的手术结局.
这项比较回顾性队列研究包括17只研究眼（10例患者），患有不受控制的葡萄膜炎，需要Retisert和Ahmed植入，55只对照眼（51例患者）患有其他类型的未受医学控制的青光眼，仅接受Ahmed治疗。
主要结局指标是眼内压（IOP），青光眼眼药水每天，最佳矫正视力，早期并发症,和1、3、6和12个月的晚期并发症。线性混合效应模型用于对IOP进行建模，青光眼每天滴剂，术后1年视力。
在1年，研究眼的平均IOP为12.24,低于对照组的15.17(P=0.04).在1年,研究眼每天使用的青光眼滴眼液的平均数量为1.4,低于对照组的2.3(P=0.03).在1年,视力变化没有统计学上的显著差异，早期并发症,以及研究和对照眼之间的晚期并发症。
与Ahmed瓣膜手术后1年的对照眼相比，接受Retisert植入术的患者眼压较低，使用的青光眼滴眼液较少。这项研究表明，从长远来看，对于接受Ahmed瓣膜植入和/或Retisert治疗的葡萄膜青光眼患者,Retisert缓释糖皮质激素(氟轻松)可改善手术结局,并且有助于控制葡萄膜炎.
这项比较回顾性队列研究包括17只研究眼（10例患者），患有不受控制的葡萄膜炎，需要Retisert和Ahmed植入，55只对照眼（51例患者）患有其他类型的未受医学控制的青光眼，仅接受Ahmed治疗。
主要结局指标是眼内压（IOP），青光眼眼药水每天，最佳矫正视力，早期并发症,和1、3、6和12个月的晚期并发症。线性混合效应模型用于对IOP进行建模，青光眼每天滴剂，术后1年视力。
在1年，研究眼的平均IOP为12.24,低于对照组的15.17(P=0.04).在1年,研究眼每天使用的青光眼滴眼液的平均数量为1.4,低于对照组的2.3(P=0.03).在1年,视力变化没有统计学上的显著差异，早期并发症,以及研究和对照眼之间的晚期并发症。
与Ahmed瓣膜手术后1年的对照眼相比，接受Retisert植入术的患者眼压较低，使用的青光眼滴眼液较少。这项研究表明，从长远来看，对于接受Ahmed瓣膜植入和/或Retisert治疗的葡萄膜青光眼患者,Retisert缓释糖皮质激素(氟轻松)可改善手术结局,并且有助于控制葡萄膜炎.
